Related by context. All words. (Click for frequent words.) 71 IV melanoma 71 IV NSCLC 69 stage IIIb 67 IV metastatic melanoma 66 unresectable stage 66 Stage IIB 66 localized renal 64 stage IIIB 64 stage IIIB IV 64 leukemia AML 64 recurrent endometrial cancer 64 relapsed GBM 63 IIIA NSCLC 63 haematological cancers 63 indolent follicular non 63 Glioblastoma Multiforme 63 T1c 63 prostate cancer mCRPC 63 heavily pretreated 63 recurrent NSCLC 63 nonsmall cell lung cancer 63 medically inoperable 62 metastatic bladder 62 biliary tract cancer 62 prostate cancer HRPC 62 axitinib 62 metastatic renal cell 62 resistant hormone refractory 62 recurrent glioblastoma 62 nonmetastatic 61 refractory ovarian cancer 61 systemic anaplastic large 61 metastatic renal cell carcinoma 61 relapsed MM 61 prostate cancer CRPC 61 mitoxantrone plus 61 relapsed refractory multiple myeloma 61 ovarian carcinoma 61 recurrent glioblastoma multiforme 61 operable breast cancer 61 resistant ovarian cancer 60 histologically confirmed 60 refractory myeloma 60 platinum refractory 60 liver metastases 60 refractory colorectal cancer 60 acute myelogenous 60 multiple myeloma MM 60 peritoneal carcinomatosis 60 pediatric acute lymphoblastic 60 metastatic renal 60 mCRPC 60 EGFR mutation positive 60 pancreatic adenocarcinoma 60 relapsed multiple myeloma 60 Stage IIIb 60 lymphocytic leukemia 60 Waldenstrom macroglobulinemia 60 mRCC 60 locoregional recurrence 60 refractory CTCL 60 stage IIIA 60 leukemia ALL 59 Wilms tumors 59 locoregional 59 malignant pleural mesothelioma 59 systemic ALCL 59 gemcitabine carboplatin 59 elacytarabine 59 taxane refractory 59 recurrent ovarian 59 underwent resection 59 epithelial ovarian cancer 59 stage IIIb IV 59 NSCLC 59 multicenter Phase 59 T1a 59 refractory acute myeloid 59 inoperable pancreatic cancer 59 immune thrombocytopenic purpura ITP 59 recurrent metastatic 59 cytoreduction 59 metastatic gastric 59 Hodgkin lymphoma HL 59 HER2 positive metastatic breast 59 completely resected 59 adjuvant cisplatin 59 Free Survival PFS 59 resected pancreatic cancer 59 relapsed refractory 59 nasopharyngeal carcinoma 59 CR nPR 59 tumors GIST 59 visceral metastases 58 metastatic lung cancer 58 refractory multiple myeloma 58 Hepatocellular Carcinoma HCC 58 refractory AML 58 extracapsular extension 58 paclitaxel carboplatin 58 KRAS wild 58 relapsed Acute Myeloid 58 ABSORB trial 58 fallopian tube carcinoma 58 unresectable 58 advanced hepatocellular carcinoma 58 prostate carcinoma 58 myelofibrosis MF 58 renal cell carcinoma 58 LHRH receptor positive 58 satraplatin Phase 58 HuMax EGFr 58 pT3 58 pancreatic carcinoma 58 multicenter phase 58 relapsing remitting MS RRMS 58 advanced NSCLC 58 Folfox 58 refractory metastatic 58 histologic subtype 58 minimally symptomatic 58 refractory metastatic colorectal cancer 58 Decitabine 58 metastatic malignant melanoma 58 trastuzumab DM1 58 docetaxel Taxotere R 58 colorectal carcinoma 58 metastatic HRPC 58 clinically localized prostate 58 squamous histology 58 assessing T DM1 58 farletuzumab 58 acute myeloid 58 recurrent colorectal cancer 58 pegylated liposomal doxorubicin 58 chemoradiotherapy 57 resected 57 standard chemotherapy regimen 57 NSCL cancer 57 phase IIb trial 57 underwent liver transplantation 57 HER2 positive breast cancer 57 castrate resistant 57 phase IIb study 57 smoldering myeloma 57 severe oral mucositis 57 HNSCC 57 pT2 57 KRAS mutations occur 57 hepatorenal syndrome 57 phase Ib 57 Alocrest 57 registrational trial 57 cholangiocarcinoma 57 Non Hodgkins lymphoma 57 metastatic kidney 57 distant metastasis 57 grade cervical intraepithelial 57 Kaplan Meier estimate 57 follicular Non Hodgkin 57 non hodgkin lymphoma 57 castrate resistant prostate cancer 57 PSMA ADC 57 cutaneous melanoma 57 cisplatin vinorelbine 57 resectable 57 relapsing multiple sclerosis 57 locoregional disease 57 including eniluracil ADH 57 lymphocytosis 57 progression TTP 57 metastatic malignant 57 AVAiL 57 advanced medullary thyroid 57 antibody MAb 57 pCR 57 refractory indolent non 57 liver metastasis 57 Phase #/#a trial 57 metastatic CRC 57 ErbB2 positive 57 mCRC patients 57 recurrent squamous cell carcinoma 57 pancreatic NET 57 Surgical resection 57 non resectable 57 thymoma 57 cervical carcinoma 57 PEGylated interferon beta 1a 57 Virulizin ® 57 castration resistant prostate cancer 57 Metastatic breast cancer 57 Acute Myeloid Leukaemia AML 57 biochemical relapse 57 CLL SLL 57 metastatic melanoma 57 lymph node involvement 57 relapsed ovarian cancer 57 unresectable Stage III 57 randomized Phase IIb 57 Evoltra ® 57 lintuzumab 57 medullary thyroid cancer 57 MALT lymphoma 57 ASA# 57 alvespimycin 57 neoadjuvant chemotherapy 57 underwent surgical resection 57 gemcitabine cisplatin 56 metastatic hormone refractory 56 pancreatic islet cell 56 non splenectomized 56 metastatic colorectal 56 metastatic ovarian cancer 56 low dose cytarabine 56 brain metastases 56 macroglobulinemia 56 lymph node metastases 56 hormone refractory 56 BR.# 56 oral clodronate 56 IMA# 56 cilengitide 56 previously untreated follicular 56 gastric lymphoma 56 glufosfamide 56 nodal metastasis 56 antiretroviral naïve 56 unresectable tumors 56 relapsed SCLC 56 plus gemcitabine 56 TTR amyloidosis 56 cisplatin chemotherapy 56 Acute Myelogenous Leukemia AML 56 bortezomib refractory 56 hepatocellular carcinoma liver 56 Amrubicin 56 relapsed AML 56 chronic myeloid 56 neurologic progression 56 Hormone Refractory Prostate Cancer 56 hepatocellular cancer 56 ankylosing spondylitis AS 56 relapsed leukemia 56 autoantibody positive 56 anaplastic astrocytoma 56 Phase Ib study 56 FOLFOX regimen 56 rALLy clinical trial 56 PROSTVAC VF 56 myeloproliferative disorder 56 myelogenous leukemia 56 oral ridaforolimus 56 forodesine 56 HBeAg negative 56 cell lymphoma ALCL 56 ELACYT 56 dexpramipexole 56 basal cell carcinoma BCC 56 Nexavar sorafenib 56 dose cohort 56 metachronous 56 rhabdoid 56 recurrent GBM patients 56 debulking surgery 56 renal tumors 56 mg/m2 dose 56 taxane chemotherapy 56 invasive ductal 56 5-FU/LV 56 iniparib BSI 56 autologous transplants 56 renal carcinoma 56 metastatic colon cancer 56 glioblastoma brain tumor 56 peritoneal cancer 56 Mantle Cell Lymphoma 56 decompensated liver disease 56 malignant lymphoma 56 Ceflatonin 56 opioid induced constipation OIC 56 lupus nephritis 56 RECORD1 56 acute lymphoblastic 56 Radical prostatectomy 56 leukemia CLL 56 advanced pancreatic neuroendocrine 56 metastatic RCC 56 Lung transplantation 56 Leukemia AML 56 Pemetrexed 56 Adjuvant chemotherapy 56 invasive carcinoma 56 hepatoblastoma 56 chemotherapy cisplatin 56 Acute myeloid leukemia 56 BRAF V# mutation 56 hA# 56 urothelial carcinoma 56 MVA MUC1 IL2 56 receptor tyrosine kinase inhibitor 56 metastatic castration resistant 56 Annamycin 56 metastatic GIST 56 gastric adenocarcinoma 56 preoperative chemotherapy 56 acute leukemias 56 Phase IIIb clinical 55 abiraterone 55 surgical debulking 55 Chronic Myelogenous Leukemia CML 55 astrocytoma 55 Allovectin 7 55 Bayer HealthCare Onyx Pharmaceuticals 55 bile duct cancers 55 Alessandro Riva 55 non metastatic osteosarcoma 55 CYT# potent vascular disrupting 55 TEMSO 55 epithelial ovarian 55 breast carcinoma 55 dosing cohort 55 heavily pretreated patients 55 relapsed mantle 55 refractory prostate cancer 55 CTAP# Capsules 55 paclitaxel poliglumex 55 differentiated thyroid 55 Myelodysplasia 55 PCNSL 55 recurrent GBM 55 multicenter Phase II 55 seminoma 55 parathyroid carcinoma 55 malignant ascites 55 ipsilateral breast 55 nonsquamous 55 recurrent ovarian cancer 55 gastric carcinoma 55 LUX Lung 55 biliary cancer 55 doublet chemotherapy 55 metastatic liver 55 metastatic bone 55 surgically resectable 55 indolent lymphoma 55 Myelodysplastic Syndrome MDS 55 papillary renal cell carcinoma 55 NMIBC 55 pediatric malignancies 55 lumiliximab 55 velafermin 55 anti angiogenic therapy 55 leiomyosarcoma 55 transitional cell carcinoma 55 relapsing MS 55 recurrent glioblastoma multiforme GBM 55 BrachySil TM 55 lung metastasis 55 chronic HCV genotype 55 Stage IIIb IV 55 neuroblastoma tumor 55 imatinib Gleevec ® 55 acute myelogenous leukemia AML 55 ® natalizumab 55 metastatic carcinoma 55 squamous cell carcinoma SCC 55 untreated metastatic colorectal 55 fistulizing Crohn disease 55 PRESEPT study 55 HRPC ovarian cancer 55 vidofludimus 55 carcinoma HCC 55 superficial bladder cancer 55 rituximab refractory 55 Aplidin 55 taxane chemotherapy administered 55 relapsed CLL 55 gastrointestinal stromal tumors 55 phase IIb 55 Adjuvant therapy 55 hepatectomy 55 ZACTIMA 55 humanised monoclonal antibody 55 Leukemia lymphoma 55 prior chemotherapy regimens 55 metastatic pancreatic cancer 55 RECIST criteria 55 Proxinium TM 55 neoadjuvant 55 BRAF V#E mutation 55 screen Tootsie MASH 55 pain palliation 55 metastatic pancreatic 55 liver resection 55 tumor recurrence 55 Hodgkin Lymphoma 55 colon carcinoma 55 pertuzumab 55 postoperative chemotherapy 55 synovial cell 55 distant metastases 55 diffuse gastric 55 Slyly witty writer 55 Motesanib 55 HQK 55 refractory SCLC 55 prostate carcinomas 55 oral Hycamtin 55 Cloretazine ® 55 entinostat 55 CMV disease 55 liposomal doxorubicin 55 mycosis fungoides 55 hPAM4 55 achieved ACR# 55 refractory Hodgkin 55 iniparib 55 sunitinib malate 55 evaluating tivozanib 55 hepatocellular carcinomas 55 concurrent chemoradiation 55 GISTs 55 remission induction 55 recurrent malignant glioma 54 soft tissue sarcomas 54 PROSTVAC ® 54 BRIM2 54 MAGE A3 ASCI 54 mildly symptomatic 54 alveolar rhabdomyosarcoma 54 5-fluorouracil/leucovorin 54 ixabepilone 54 IIIB NSCLC 54 malignant pancreatic 54 cancer mCRC 54 grade glioma 54 seminal vesicle invasion 54 phase IIb clinical 54 sodium thiosulfate STS 54 follicular non 54 refractory chronic lymphocytic 54 diffuse intrinsic pontine glioma 54 haematologic malignancies 54 VELCADE melphalan 54 motesanib 54 nonalcoholic steatohepatitis 54 MDS AML 54 BCIRG 54 splenectomized 54 FOLFOX6 54 rindopepimut 54 carcinoid tumors 54 randomized controlled Phase 54 Tavocept 54 biochemical recurrence 54 metastatic CRPC 54 HIV HCV coinfected 54 Axitinib 54 Doxil ® 54 chemoradiation therapy 54 metastatic castrate resistant 54 p#HER# positive 54 advanced carcinoid 54 galiximab 54 ToGA 54 refractory CLL 54 Aflibercept 54 indolent NHL 54 de novo AML 54 metastatic testicular cancer 54 PROSTVAC TM 54 Rectal cancer 54 neuroendocrine cancers 54 Vicinium TM 54 metastatic prostate cancer 54 cell carcinoma RCC 54 androgen independent 54 Burkitt Lymphoma 54 urothelial bladder cancer 54 MAGE A3 54 PAOD 54 OncoVAX ® 54 metastic 54 enzastaurin 54 curative resection 54 TACI Ig 54 hepatocellular carcinoma HCC 54 CRLX# 54 oblimersen 54 nonmetastatic prostate cancer 54 gastrointestinal stromal tumor GIST 54 neoadjuvant therapy 54 DCVax ® Brain 54 papillary RCC 54 demonstrated antitumor activity 54 carcinoid 54 subcutaneous methylnaltrexone 54 tanespimycin 54 relapsed ALL 54 MYCN amplification 54 free survival PFS 54 Renal Cell Carcinoma RCC 54 advanced HER2 positive 54 regorafenib 54 Garcia Manero 54 Malignant Melanoma 54 Exherin TM 54 ZACTIMA TM ZD# 54 Median survival 54 metastatic colorectal carcinoma 54 Belldegrun 54 elotuzumab 54 ER CHOP 54 rectal carcinoma 54 colorectal liver 54 gefitinib Iressa 54 non squamous 54 neoadjuvant treatment 54 bendamustine 54 sarcomatoid 54 Brentuximab Vedotin SGN 54 Sezary syndrome 54 lobular carcinoma 54 gastrointestinal cancers 54 anti EGFR antibody 54 TroVax ® 54 hormone refractory prostate cancer 54 recurrent genital herpes 54 sarcoma 54 cell lymphoma CTCL 54 obatoclax 54 asymptomatic metastatic 54 Prognostic factors 54 FOLOTYN ® 54 lymphoma CTCL 54 XL# administered orally 54 Relapsed Refractory 54 figitumumab 54 CTEPH 54 % CI #.#-#.# [003] 54 adjuvant radiotherapy 54 Hodgkin lymphoma NHL 54 relapsed Hodgkin lymphoma 54 para aortic 54 gemcitabine Gemzar ® 54 ara C 54 hepatocellular carcinoma 54 Plicera 54 INCB# [001] 54 TNM classification 54 non hodgkins lymphoma 54 chemoresistant 54 Tumor shrinkage 54 refractory NSCLC 54 OncoVEX GM CSF 54 RRMS patients 54 thrombocytopenic 54 adjuvant therapy 54 registrational 54 CR CRu 54 somatostatin analog 54 Follicular Lymphoma 54 Acute Myeloid Leukemia AML 54 invasive candidiasis 54 AVOREN 54 myelodysplastic syndromes MDS 54 alpha folate receptor 54 intravesical therapy 54 prostate cancer AIPC 54 Cloretazine 54 BARACLUDE ® 54 hematological malignancy 54 chemo radiotherapy 54 Myelodysplastic Syndrome 54 dasatinib Sprycel 54 evaluable patients 54 phase IIa 54 BR.# study 54 squamous non 54 anthracycline taxane 54 pilocytic astrocytoma 54 overt hepatic encephalopathy HE 54 unresectable locally advanced 54 mapatumumab 54 disease progression TTP 54 Onrigin 53 pancreatic colorectal 53 PSADT 53 Tarvacin Anti Cancer 53 Randomized Phase II 53 Phase IIb clinical trials 53 investigational monoclonal antibody 53 taxane therapy 53 Darusentan 53 hormone refractory metastatic prostate 53 gastrointestinal stromal tumors GIST 53 pancreatic colon 53 bone metastasis 53 Carcinoma 53 Infusion reactions 53 Toxicities 53 trabectedin 53 cetuximab Erbitux 53 Omacetaxine 53 cervical intraepithelial neoplasia 53 R0 resection 53 BRCA deficient 53 sunitinib Sutent 53 rALLy 53 LymphoStat B belimumab 53 colorectal cancer liver metastases 53 BAY #-# 53 Subgroup analysis 53 pelvic malignancies 53 diagnosed GBM 53 gemcitabine chemotherapy 53 histologies 53 pheochromocytoma 53 neuroendocrine tumors 53 cell carcinoma 53 PRIMO CABG 53 steroid refractory ulcerative 53 HER2 + 53 evaluating Nexavar 53 treatment naïve genotype 53 dose dexamethasone 53 estramustine 53 proliferative retinopathy 53 Hepatocellular Carcinoma 53 oral deforolimus 53 lymphadenectomy 53 surgically resected 53 Phase Ib II 53 efficacy endpoint 53 SIR Spheres 53 CTCL 53 pelvic lymphadenectomy 53 prostate cancer CaP 53 gastrointestinal stromal tumor 53 paclitaxel Taxol R 53 randomized Phase 53 oral JAK#/JAK# inhibitor 53 metastatic disease 53 dacarbazine DTIC 53 hereditary pancreatitis 53 bladder carcinoma 53 sorafenib 53 mertansine 53 tuberous sclerosis TS 53 prospectively defined 53 plus dexamethasone 53 huN# DM1 53 AML acute myeloid 53 refractory systemic anaplastic 53 radiation chemoradiation 53 achieved CCyR 53 Glioblastoma multiforme GBM 53 Gleevec resistant 53 afatinib 53 HGS ETR1 53 Acute Myelogenous Leukemia 53 dose escalation Phase 53 metaglidasen 53 refractory lymphoma 53 idiopathic thrombocytopenic purpura ITP 53 precursor lesions 53 intravenous belinostat 53 infiltrating ductal carcinoma 53 Chronic Myeloid Leukemia 53 advanced epithelial ovarian 53 allogeneic HSCT 53 AML Leukemia 53 STRIDE PD 53 randomized Phase 2b 53 Tarceva TM 53 docetaxel chemotherapy 53 palifosfamide 53 HER2 positive 53 Quinamed 53 PEG IFN 53 gastrointestinal stromal 53 unresectable liver cancer 53 myelodysplastic syndrome MDS 53 evaluable subjects 53 Stage IV 53 leukemia APL 53 OHR/AVR# 53 luteinizing hormone releasing 53 novel therapeutic antibodies 53 vismodegib 53 doxorubicin docetaxel 53 cell acute lymphoblastic 53 ductal breast cancer 53 grade cervical dysplasia 53 cisplatin resistant 53 small lymphocytic lymphoma 53 metastatic cancer 53 neratinib 53 secondary hyperparathyroidism 53 neuroendocrine carcinoma 53 adjuvant radiation 53 OncoVex 53 syngeneic 53 baminercept 53 hormone receptor negative 53 EndoTAGTM 1 53 DCVax R Brain 53 castration resistant 53 MCyR 53 paclitaxel cisplatin 53 darapladib 53 sorafenib Nexavar ® 53 huC# DM4 53 HER2 positive cancers 53 Bezielle 53 cytologically confirmed 53 Wilm Tumor 53 alveolar soft 53 epithelial tumors 53 colorectal adenoma 53 olaparib 53 pancreatic cancer 53 CLARITY study 53 relapsing remitting multiple sclerosis 53 cell lung cancer 53 efaproxiral 53 CHOP chemotherapy 53 erlotinib Tarceva 53 lung metastases 53 ovarian prostate 53 LBH# 53 FOLFOX4 53 OvaRex ® MAb 53 SCCHN 53 advanced adenoma 53 CIN3 53 B Cell Lymphoma 53 ACTEMRA TM 53 transplantation HCT 53 follicular lymphoma 53 steroid refractory GvHD 53 situ LCIS 53 #mg BID [001] 53 IMC #B 53 baseline LDH 53 Phase Ib clinical 53 symptomatic VTE 53 follicular lymphomas 53 radical prostatectomy RP 53 glioblastoma GBM 53 invasive lobular 53 Xanafide 53 pleural mesothelioma 53 anti leukemic 53 pancreatic neuroendocrine tumors 53 breast carcinomas 53 Idiopathic pulmonary fibrosis 53 CR# vcMMAE 53 Degarelix 53 refractory cutaneous T 53 node metastases 53 zanolimumab 53 metastatic androgen independent 53 p# biomarker 53 urothelial cancer 53 gastric cancer 53 median survivals 53 Wilms Tumor 53 docetaxel Taxotere ® 53 prostate cancer PCa 53 L BLP# 53 virus HCV protease inhibitor 53 deCODE ProstateCancer TM 53 tumor progression TTP 53 BRIM3 53 ductal carcinomas 53 colorectal breast 53 carboplatin paclitaxel 53 GvHD 53 vascular disrupting agent 52 Gleevec imatinib 52 Ceplene/IL-2 52 chronic granulomatous disease 52 bone metastases 52 Ozarelix 52 Daclizumab 52 myelofibrosis 52 Chronic lymphocytic leukemia CLL 52 acute promyelocytic leukemia 52 glioblastoma multiforme GBM 52 adjuvant trastuzumab 52 decitabine 52 radiation sensitizer 52 DEB# 52 Phase IIb trials 52 radical nephrectomy 52 non squamous NSCLC 52 follicular NHL 52 adjuvant chemotherapy 52 H. pylori eradication 52 lymphomas leukemias 52 Acute Myeloid Leukaemia 52 Arzerra ofatumumab 52 pulmonary metastasis 52 Hurler syndrome 52 Cell Lymphoma 52 cediranib 52 Halaven 52 evaluating REVLIMID 52 Randomized Phase 52 gemcitabine Gemzar 52 GVAX 52 ThermoDox R 52 Ophena TM 52 palliative radiotherapy 52 Allovectin 7 ® 52 renal cell carcinomas 52 FOLFIRI alone 52 hematologic disorders 52 randomized Phase III 52 mucinous 52 hypophosphatasia 52 esophageal gastric 52 colorectal liver metastases 52 temozolomide Temodar 52 Phase III randomized controlled 52 tumor resection 52 Zybrestat 52 Dacogen injection 52 breast pancreatic 52 gastric cancers 52 Torisel 52 non metastatic resectable 52 Insegia 52 complete cytogenetic response 52 Arranon 52 radiochemotherapy 52 class mGluR5 inhibitor 52 erlotinib Tarceva ® 52 evaluable 52 Burkitt lymphoma 52 liposomal amphotericin B 52 kidney allograft 52 diagnosed multiple myeloma 52 RTOG 52 dose escalation clinical 52 Safinamide 52 irinotecan chemotherapy 52 HRPC 52 Paraplatin ® carboplatin 52 Tarceva erlotinib 52 leukemia lymphoma multiple myeloma 52 valopicitabine 52 dasatinib Sprycel ® 52 HuMax CD4 52 MGd 52 Nicole Onetto MD 52 CALGB 52 allogeneic bone marrow 52 Lorianne Masuoka MD 52 malignant pheochromocytoma 52 Troxatyl 52 essential thrombocythemia ET 52 cabazitaxel 52 DIPG 52 refractory chronic myeloid 52 % CI #.#-#.# [007] 52 Phase 1a clinical 52 HuMax CD# 52 smoldering multiple myeloma 52 node dissection 52 Cotara 52 dose escalation phase 52 undetectable HBV DNA 52 cytotoxic therapy 52 panobinostat 52 polyp recurrence 52 IIIb 52 Flu Cy 52 thymic carcinoma 52 recurrent VTE 52 partial remissions 52 Chronic lymphocytic leukemia 52 Medullary thyroid cancer 52 colorectal metastases 52 Sentinel node biopsy 52 non squamous histology 52 vandetanib 52 tyrosine kinase inhibitors TKIs 52 multicenter randomized controlled 52 diabetic kidney 52 adecatumumab 52 ongoing Phase 1b 52 invasive ductal carcinoma 52 remission CR 52 liposarcoma 52 ispinesib administered 52 TTF Therapy 52 abiraterone acetate 52 dermatology biopharmaceutical company 52 lymphoblastic lymphoma 52 vemurafenib 52 Peginterferon alfa 2b 52 IMGN# 52 brivanib 52 pomalidomide 52 malignant brain 52 Metastatic 52 metastatic adenocarcinoma 52 pemphigus vulgaris 52 dirucotide MBP# 52 cyclophosphamide methotrexate 52 hepatitis C genotype 52 EOquin TM phase 52 TASQ 52 endometrial adenocarcinoma 52 pegylated interferon alfa 2b 52 KRAS mutant tumors 52 HGS ETR2 52 Acute myelogenous leukemia 52 oligodendrogliomas 52 chemoradiation 52 CRp 52 temsirolimus 52 docetaxel Taxotere 52 pretransplant 52 Papillary 52 YONDELIS 52 Prodarsan R 52 plus prednisone 52 metastatic colorectal cancer 52 imetelstat GRN#L 52 commercialize deforolimus 52 neovascular diseases 52 IIa trial 52 commercialize MDV# 52 colorectal pancreatic 52 taxotere 52 AEG# 52 Sipuleucel T 52 PANVAC VF 52 CD# mAb 52 Idiopathic Pulmonary Fibrosis 52 CC genotype 52 randomized discontinuation trial 52 soft tissue sarcoma 52 Relapsing Remitting MS 52 MELAS 52 chronic HCV 52 dose escalation trial 52 Diffuse Large B 52 angiogenesis inhibitor 52 Wilm tumor 52 CytoFab ™ 52 orthotopic 52 contralateral breast 52 Acute Leukaemia 52 cyclophosphamide chemotherapy 52 Non Hodgkins Lymphoma 52 RECIST Response Evaluation Criteria 52 Cloretazine R VNP#M 52 depsipeptide 52 childhood acute lymphoblastic 52 TEMODAL 52 NovoTTF 52 testicular cancers 52 nonsquamous histology 52 undergoing radical cystectomy 52 Cimzia TM 52 adjuvant tamoxifen 52 INSPIRE Trial Phase III 52 plasma uric acid 52 brain metastases originating 52 prostate adenocarcinoma 52 riociguat 52 neuroblastoma tumors 52 chronic HBV 52 VNP#M 52 Median progression 52 Neuvenge 52 Lilly Gemzar 52 placebo controlled clinical 52 ATL# [001] 52 Femara letrozole 52 EGFR TKI 52 Uricase PEG 52 Canvaxin 52 complete remissions 52 evaluating T DM1 52 Trastuzumab 52 HER2 expression 52 vinorelbine 52 precursor acute lymphoblastic 52 HER2 overexpression 52 recurrent prostate cancer 52 Cell Lung Cancer 52 CBLC# 52 benign prostatic hyperplasia enlarged